S
Satoru Miyano
Researcher at Tokyo Medical and Dental University
Publications - 874
Citations - 45801
Satoru Miyano is an academic researcher from Tokyo Medical and Dental University. The author has contributed to research in topics: Gene & Gene regulatory network. The author has an hindex of 84, co-authored 811 publications receiving 38723 citations. Previous affiliations of Satoru Miyano include University of Paderborn & Institute of Medical Science.
Papers
More filters
Journal ArticleDOI
Distinctive Genetic Features of Plasma Cells in POEMS Syndrome
Yuhei Nagao,Naoya Mimura,June Takeda,Motohiko Oshima,Kenichi Yoshida,Yusuke Shiozawa,Kazumasa Aoyama,Atsunori Saraya,Shuhei Koide,Yuichi Shiraishi,Kenichi Chiba,Hiroko Tanaka,Chika Kawajiri-Manako,Nagisa Hasegawa,Shio Sakai,Yusuke Takeda,Chikako Ohwada,Masahiro Takeuchi,Emiko Sakaida,Tohru Iseki,Sonoko Misawa,Koutaro Yokote,Satoru Miyano,Osamu Ohara,Satoshi Kuwabara,Masashi Sanada,Atsushi Iwama,Seishi Ogawa,Chiaki Nakaseko +28 more
TL;DR: This study performed whole exome sequencing (WES), target sequencing, and RNA sequencing of PCs in patients with POEMS syndrome in order to define its genetic profiles and found that frequently mutated genes in MM such as NRAS, KRAS, and TP53 were not identified.
Journal ArticleDOI
Post-azacitidine clone size predicts outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
Yasuhito Nannya,Magnus Tobiasson,Shinya Sato,Elsa Bernard,Shigeki Ohtake,June Takeda,Maria Creignou,Lanying Zhao,Manabu Kusakabe,Yuhei Shibata,Nobuhiko Nakamura,Mizuki Watanabe,Nobuhiro Hiramoto,Yusuke Shiozawa,Yuichi Shiraishi,Hiroko Tanaka,Kenichi Yoshida,Nobuyuki Kakiuchi,Hideki Makishima,Masahiro Nakagawa,Kensuke Usuki,Mitsumasa Watanabe,Kazunori Imada,Hiroshi Handa,Masataka Taguchi,Toru Kiguchi,Kazuma Ohyashiki,Takayuki Ichikawa,Akifumi Takaori-Kondo,Hisashi Tsurumi,Senji Kasahara,Shigeru Chiba,Tomoki Naoe,Satoru Miyano,Elli Papaemmanuil,Yasushi Miyazaki,Eva Hellström Lindberg,Seishi Ogawa +37 more
TL;DR: In this paper , the effect of gene mutations on hematological response and overall survival (OS), particularly focusing on their post-treatment clone size, was elucidated, and the authors evaluated the role of pre-treatment mutational profile as well as IWG-response have a role in better prognostication of azacitidine-treated myelodysplasia patients.
Journal ArticleDOI
Novel Pathogenic Defects Of Dead/H-Box Helicases In Myeloid Neoplasms
Chantana Polprasert,Mikkael A. Sekeres,Hideki Makishima,Bartlomiej P Przychodzen,Naoko Hosono,Richard A. Padgett,Jarnail Singh,Otrock Zaher,Sudipto Mukherjee,Manuel G. Afable,Holleh D Husseinzadeh,Sarah Mcmahon,Wenyi Shen,Dayong Huang,Kenichi Yoshida,Yuichi Shiraishi,Kenichi Chiba,Hiroko Tanaka,Satoru Miyano,Seishi Ogawa,Jaroslaw P. Maciejewski +20 more
TL;DR: Two identical twins presenting with concordant MDS and a strong family history of leukemia demonstrated several unifying features, including a clinical response to lenalidomide despite neither twin expressing the del(5q) abnormality, resulting in transfusion-independence and restoration of normal counts.
Journal ArticleDOI
Statistical model selection method to analyze combinatorial effects of snps and environmental factors for binary disease
TL;DR: A model selection method to estimate the relation of multiple SNPs, environmental factors and the binary disease trait and the genetic algorithm for choosing the optimal SNPs and environments in the sense of AIC is proposed.
Journal ArticleDOI
Prognostic Impact of Circulating Tumor DNA Status Post-Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Sousuke Nakamura,Kazuaki Yokoyama,Eigo Shimizu,Nozomi Yusa,Miho Ogawa,Tomomi Takei,Asako Kobayashi,Mika Ito,Masamichi Isobe,Takaaki Konuma,Seiko Kato,Rika Kasajima,Yuka Wada,Tokiko Nagamura-Inoue,Rui Yamaguchi,Satoshi Takahashi,Seiya Imoto,Satoru Miyano,Arinobu Tojo +18 more
TL;DR: The utility of residual circulating tumor DNA (ctDNA) status for identifying patients with AML and MDS at high risk for relapse post myeloablative alloSCT and corresponding ctDNA persistence in serum were comparably associated with higher 3-year CIR rates and inferior OS rates.